Lantheus Holdings



Credit Suisse 29th Annual Healthcare Conference

November 11, 2020

FIND > FIGHT > FOLLOW

Safe Harbor Statements

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “anticipate,” “believe,” “confident,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include : (i) the impact of the global COVID-19 pandemic on our business, financial conditions or prospects, or on the timing and enrollment of our clinical trials; (ii) continued market expansion and penetration for our commercial products, particularly DEFINITY®, in the face of segment competition and potential generic competition as a result of patent and regulatory exclusivity expirations; (iii) the global Molybdenum-99 supply; (iv) our products manufactured at Jubilant HollisterStier and our plans to develop a modified formulation of DEFINITY with Samsung Biologics; (v) our efforts in new product development, including for PyL, the Progenics prostate cancer diagnostic imaging agent, including our ability to obtain FDA approval of PyL in 2021, and new clinical applications for our products; (vi) our dependence upon third parties for the manufacture and supply of PyL and the timing of that manufacturing capacity becoming available; (vii) the continued integration of the Progenics product and product candidate portfolio following the consummation of the Progenics transaction; (viii) our capacity to use in-house manufacturing; and (ix) our ability to commercialize our products in new ex-U.S. markets; (x) the expected timing for commercialization of products we or our strategic partners may develop, including flurpiridaz F 18; (xi) our ability to develop highly contextualized assessments of disease burden using PSMA AI and (xii) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q)

All trademarks, logos and service marks on this page are the property of their respective owners.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Lantheus Holdings

Lantheus Corporate History

1956 — NEW ENGLAND NUCLEAR (NEN) FOUNDED

1976 — U.S. FDA APPROVES TECHNELITE

1981 — DUPONT PURCHASES NEN

1990 — U.S. FDA APPROVES CARDIOLITE

1991 — DUPONT FORMS VENTURE WITH MERCK CALLED DUPONT MERCK

1998 — DUPONT BUYS MERCK'S INTEREST, BECOMES DUPONT PHARMACEUTICALS

2001 — BRISTOL MYERS SQUIBB CO. PURCHASES DUPONT PHARMACEUTICALS

2001 — U.S. FDA APPPROVES DEFINITY

2008 — BMS SELLS BMS MEDICAL IMAGING TO AVISTA CAPITAL PARTNERS, LANTHEUS MEDICAL IMAGING LAUNCHED

2015 — LANTHEUS HOLDINGS IPO ON NASDAQ

2016 — U.S FDA APPROVES RELISTOR (SC)

2016 — U.S FDA APPROVES RELISTOR (TABLETS)

2018 — U.S. FDA APPROVES AZEDRA

2020 — LANTHEUS HOLDINGS CLOSES MERGER WITH PROGENICS PHARMACEUTICALS

Serving Large, Growing Markets

Global Diagnostic Imaging Market
($B)



Source: GlobalData, Sept 2019

Global Nuclear Medicine Market
($B)



Source: MedRaysIntell, July 2019

* 5-year CAGR

Key Commercial Products

DEFINITY®
VIAL FOR (Perflutren Lipid Microsphere)
INJECTABLE SUSPENSION

- Steady sequential recovery
- Two-year average growth rate in low teens

TechneLite
Technetium Tc 99m Generator

- 13.6% sequential growth
- Steady molybdenum-99m supply

Xenon Xe 133 Gas

- Hospital protocols currently limiting use of inhalation respiratory procedures due to COVID-19 transmission concerns

AZEDRA®
iobenguane I 131 injection for intravenous use

- Continued utilization in established Center of Excellence network
- Hospitals remain open to patient-access only impeding commercial efforts for incremental patient identification
- Optimizing our iodine manufacturing network

Significant U.S. Echocardiography Market Opportunity for DEFINITY Remains

~2% Annual Growth Rate in Total Echocardiograms

DEFINITY®
VIAL FOR (Perflutren Lipid Microsphere)
INJECTABLE SUSPENSION

Over 80% market share for image enhancing agents[1]



Circles not drawn to scale.
1 AMR Echocardiography Monthly Monitor, December 2019, 2 20% of echocardiograms result in sub-optimal images. Source: Kurt M et al. J Am Coll Cardiol. 2009;53(9):802-810,
3 LMI estimate.

Total US Nuclear Imaging Studies have been Relatively Stable Since 2017; Forecasted WW Growth in Radiotherapeutics will Drive Need for Diagnostics

Annual U.S. Nuclear Imaging Studies
Millions; Percent of Total



Forecast Global Radiotherapeutics Market
USD Millions



1 Tc-99m studies make up the vast majority of SPECT studies.
Source: AMR PADDS 2018 database, MEDrays intell 2019 Nuclear Medicine Report; LMI internal market assessment

AZEDRA: The First and Only FDA-Approved Treatment for PPGL*

AZEDRA®
iobenguane I 131 injection for intravenous use

First and only FDA-approved treatment for adults and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy

Strategies to increase AZEDRA demand and pull through

- Increase product awareness and patient identification
- Ensure manufacturing capacity matches increasing product demand

* Pheochromocytoma and Paraganglioma

Lantheus Holdings

Prostate Cancer PET Imaging: Large Addressable Market of ~$500M

PyL NDA Submitted to FDA on September 29, 2020



Status of New Drug Application (NDA)

- Submitted on September 29, 2020 with request for Priority Review
  - Priority Review: 6-months from time of acceptance, if granted
  - Standard Review: 10-months from time of acceptance
- Expect to receive notification from FDA confirming acceptance of the filing for review by early December 2020

Prostate Cancer Statistics[1]

- 192,000 new cases of prostate cancer each year
- 3.2M men annually in the US impacted by prostate cancer

Prostate Cancer PET Imaging Addressable Market[2]

- 130K annual PET scan potential based on an incidence of ~50K men with biochemical recurrence in addition to ongoing imaging in the prevalent population
- ~$500M annual prostate cancer PET imaging market potential

(1) National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. Accessed at https://seer.cancer.gov/statfacts/html/prost.html on March 15, 2019. (2) Addressable market based on: current management estimates, internal data and observed market price.

PyL: Strong Diagnostic Performance Across Prostate Cancer Disease Continuum

		PPV[1] for the detection of tumor in the prostate gland[2]	PPV for the detection of pelvic lymph nodes (LN) lesions	PPV for the detection of extra pelvic metastatic lesions (LN, bone, soft tissues)
OSPREY cohort A N=252	High risk prostate cancer	100%	78-91%	NA
OSPREY cohort B N=93	Recurrent/metastatic prostate cancer with presumptive radiologic evidence on conventional imaging and feasible for biopsy	NA	75-94%	83-86%
CONDOR N=208	Biochemical recurrence of prostate cancer with negative or equivocal baseline imaging	75-83%	67-73%	67-70%

Administered in ~3,500 patients with prostate cancer globally

2 pivotal studies (OSPREY and CONDOR, N~600)

Company- or investigator-sponsored studies (N~900)

Clinical use reported in the literature (N~2,000)

(1) Positive Predictive Value; (2) There was no pathology data for four patients and indeterminate histopathology results for one patient, N=247.

PSMA-Targeted Prostate Cancer Imaging Awareness Website Launched

FoursightProstateCancer.com

PyL Manufacturing and Distribution Process

Batch Process Produces a Large Quantity of Doses When Compared to a Generator-Driven Process

F 18 is synthesized on a cyclotron

Early hours of the morning

PyL is manufactured in a synthesis box

Finished as a bulk vial; drawn into patient-ready doses

"Out the door" at ~11am

Easily transported within a ~3 hour radius

Patient is injected and scanned

Majority of patient studies performed in the afternoon

Lantheus Holdings

Robust Pipeline with Promising Value Drivers



(1) Medical Device; (2) GE Healthcare is conducting the second Phase 3 study; (3) PDL1 tracer with ongoing Phase 1 clinical development conducted by NanoMab; (4) Licensed in Europe by ROTOP and in Japan by FUJI; (5) Clinical development program conducted by Bayer; (6) Clinical development program conducted by Cerevast; (7) Clinical development program conducted by CarThera.

Lantheus Holdings

The Latest Strategic Partnerships Across Our Portfolio

REGENERON

BAYER

Clinical supply agreements with both Regeneron and Bayer to use PyL to assess PSMA expression levels in their respective clinical trials for prostate cancer therapeutics

Deal terms include a supply price

GE Healthcare

FDA 510(k) of the artificial intelligence enabled automated bone scan index (aBSI) on GE's Precision Healthcare System for assisting the evaluation of prostate cancer bone metastases

Deal terms not disclosed

INSIGHTEC®

Strategic collaboration for use of microbubbles in combination with MR-guided Focused Ultrasound treatment for glioblastoma

Deal terms include a transfer price and royalties

Lantheus Holdings

Financial Highlights[1]

Cash and cash equivalents at 9/30/2020: $88M

USD in millions, except EPS

Q3 2019 | Q3 2020

Revenues



Net Income/(Loss)



GAAP EPS

Free Cash Flow



Adjusted Net Income[2]



Adjusted EPS[2]



(1) See supplemental information at www.lantheus.com. (2) See slide 25-26 for a reconciliation of GAAP to non-GAAP financials.

Lantheus Holdings

Key Takeaways for Q3 2020

Steady financial recovery led by DEFINITY sales and synergy capture

PyL NDA submitted September 2020

Prostate cancer PET imaging presents a large addressable market of ~$500M

Entered into several strategic partnerships across our portfolio

Resumed new patient enrollment in our Phase 2 1095 trial in the US and Canada

Strong liquidity position

Lantheus Holdings

Lantheus Holdings



FIND > FIGHT > FOLLOW

Appendix

Condensed Consolidated Statement of Operations

(in thousands, except per share data - unaudited)	Q3 2020 Amount	Q3 2020 % Revenue	Q3 2019 Amount	Q3 2019 % Revenue	% Increase/ (Decrease)
Revenues	$ 88,544	100.0	$ 85,776	100.0	3.2
Cost of goods sold	52,284	59.0	44,187	51.5	18.3
Gross profit	36,260	41.0	41,589	48.5	(12.8)
Operating expenses					
Sales and marketing	11,609	13.1	10,151	11.8	14.4
General and administrative	18,217	20.6	18,061	21.1	0.9
Research and development	11,684	13.2	4,860	5.7	140.4
Total operating expenses	41,510	46.9	33,072	38.6	25.5
Operating (loss) income	(5,250)	(5.9)	8,517	9.9	(161.6)
Interest expense	2,808	3.2	2,356	2.7	19.2
Other (income) loss	(596)	(0.7)	804	0.9	(174.1)
(Loss) income before income taxes	(7,462)	(8.4)	5,357	6.2	(239.3)
Income tax (benefit) expense	(1,076)	(1.2)	501	0.6	(314.8)
Net (loss) income	$ (6,386)	(7.2)	$ 4,856	5.7	(231.5)
Net (loss) income per common share - diluted	$ (0.10)		$ 0.12		
Weighted-average common shares outstanding - diluted	66,820		40,286		
Adjusted net income	$ 2,418	2.7	$ 11,253	13.1	(78.5)
Adjusted net (loss) income per common share - diluted	0.04		0.28		(87.1)
Weighted-average common shares outstanding - diluted	67,006		40,286		

Non-GAAP Financial Measures

(in thousands, except per share data - unaudited)	Q3 2020 Amount	Q3 2020 % Revenue	Q3 2019 Amount	Q3 2019 % Revenue	% Increase/Decrease (Decrease)
Revenues	88,544	100.0	85,776	100.0	3.2
COGS	46,555	52.6	43,168	50.3	7.8
Gross Profit	41,989	47.4	42,608	49.7	(1.5)
Operating Expenses					
Sales and Marketing	10,855	12.3	9,633	11.2	12.7
General and Administrative	13,456	15.2	10,936	12.7	23.0
Research and Development	10,919	12.3	4,472	5.2	144.2
Total Operating Expenses	35,230	39.8	25,041	29.2	40.7
Operating (loss) income	6,759	7.6	17,567	20.5	(61.5)
Interest Expense	2,808	3.2	2,356	2.7	19.2
Other Expense (Income)	(211)	-0.2	804	0.9	(126.2)
Income b4 Income Taxes	4,162	4.7	14,407	16.8	(71.1)
Income tax (benefit) expense	1,744	2.0	3,154	3.7	(44.7)
Net Income	2,418	2.7	11,253	13.1	(78.5)
NI per common share-diluted	$0.04		$0.28		(87.1)
Wtd Avg Common - diluted	67,006		40,286		

Consolidated Segment Revenues Analysis
(in thousands – unaudited)

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2020	2019	% Change	2020	2019	% Change
United States						
DEFINITY	$ 53,792	$ 50,917	5.6 %	$ 148,346	$ 154,099	(3.7)%
TechneLite	17,652	18,281	(3.4)%	52,599	55,204	(4.7)%
Other nuclear	11,571	9,355	23.7 %	26,437	28,006	(5.6)%
Rebates and allowances	(5,540)	(3,903)	41.9 %	(13,763)	(12,035)	14.4 %
Total United States	77,475	74,650	3.8 %	213,619	225,274	(5.2)%
International						
DEFINITY	1,637	1,478	10.8 %	4,239	4,036	5.0 %
TechneLite	3,837	3,466	10.7 %	10,897	10,794	1.0 %
Other nuclear	5,596	6,186	(9.5)%	16,507	17,901	(7.8)%
Rebates and allowances	(1)	(4)	(75.0)%	(4)	(14)	(71.4)%
Total International	11,069	11,126	(0.5)%	31,639	32,717	(3.3)%
Worldwide						
DEFINITY	55,429	52,395	5.8 %	152,585	158,135	(3.5)%
TechneLite	21,489	21,747	(1.2)%	63,496	65,998	(3.8)%
Other nuclear	17,167	15,541	10.5 %	42,944	45,907	(6.5)%
Rebates and allowances	(5,541)	(3,907)	41.8 %	(13,767)	(12,049)	14.3 %
Total Revenues	$ 88,544	$ 85,776	3.2 %	$ 245,258	$ 257,991	(4.9)%

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands, except per share data – unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2020	2019	2020	2019
Net (loss) income	$ (6,386)	$ 4,856	$ (10,061)	$ 21,217
Stock and incentive plan compensation	3,992	3,423	10,452	9,580
Amortization of acquired intangible assets	4,768	451	6,087	1,353
Acquired debt fair value adjustment	(385)	—	(385)	—
Contingent consideration fair value adjustments	800	—	800	—
Non-recurring refinancing related fees	—	—	460	—
Extinguishment of debt	—	—	—	3,196
Strategic collaboration and license costs	—	—	—	300
Integration costs	855	—	4,428	—
Acquisition-related costs	1,593	5,176	10,522	5,176
Impairment of long-lived assets	—	—	7,275	—
Other	—	—	(75)	—
Income tax effect of non-GAAP adjustments[a]	(2,819)	(2,653)	(8,265)	(7,449)
Adjusted net income	$ 2,418	$ 11,253	$ 21,238	$ 33,373
Adjusted net income, as a percentage of revenues	2.7 %	13.1 %	8.7 %	12.9 %

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2020	2019	2020	2019
Net (loss) income per share - diluted	$ (0.10)	$ 0.12	$ (0.20)	$ 0.53
Stock and incentive plan compensation	0.06	0.08	0.21	0.24
Amortization of acquired intangible assets	0.08	0.01	0.12	0.03
Acquired debt fair value adjustment	(0.01)	—	(0.01)	—
Contingent consideration fair value adjustments	0.01	—	0.01	—
Non-recurring refinancing related fees	—	—	0.01	—
Extinguishment of debt	—	—	—	0.08
Strategic collaboration and license costs	—	—	—	0.01
Integration costs	0.01	—	0.09	—
Acquisition-related costs	0.02	0.13	0.21	0.12
Impairment of long-lived assets	—	—	0.14	—
Income tax effect of non-GAAP adjustments[a]	(0.03)	(0.06)	(0.16)	(0.18)
Adjusted net income per share - diluted	$ 0.04	$ 0.28	$ 0.42	$ 0.83
Weighted-average common shares outstanding -	67,006	40,286	50,210	40,123

(a) The income tax effect of the adjustments between GAAP net (loss) income and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.

(b) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP net loss position

Reconciliation of Free Cash Flow
(in thousands – unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2020	2019	2020	2019
Net cash provided by operating activities	$ 8,575	$ 26,442	$ 15,827	$ 57,963
Capital expenditures	(3,736)	(3,336)	(8,689)	(17,320)
Free cash flow	$ 4,839	$ 23,106	$ 7,138	$ 40,643

Condensed Consolidated Balance Sheet
(in thousands – unaudited)

	September 30, 2020	December 31, 2019
Assets		
Current assets		
Cash and cash equivalents	$ 87,994	$ 92,919
Accounts receivable, net	49,206	43,529
Inventory	37,623	29,180
Other current assets	9,709	7,283
Total current assets	184,532	172,911
Property, plant and equipment, net	122,381	116,497
Intangibles, net	384,747	7,336
Goodwill	57,765	15,714
Deferred tax assets, net	69,345	71,834
Other long-term assets	60,824	21,627
Total assets	$ 879,594	$ 405,919
Liabilities and stockholders' equity		
Current liabilities		
Current portion of long-term debt and other borrowings	$ 18,138	$ 10,143
Accounts payable	24,070	18,608
Accrued expenses and other liabilities	39,792	37,360
Total current liabilities	82,000	66,111
Asset retirement obligations	13,962	12,883
Long-term debt, net and other borrowings	204,669	183,927
Other long-term liabilities	65,384	28,397
Total liabilities	366,015	291,318
Total stockholders' equity	513,579	114,601
Total liabilities and stockholders' equity	$ 879,594	$ 405,919

OSPREY and CONDOR: Safety of 18F-DCFPyL in All Subjects

Preferred Term	All Subjects N=593 n (%)
Any treatment-emergent Adverse Event	30 (5.1)
Headache	9 (1.5)
Dysgeusia	9 (1.3)
Fatigue	4 (0.7)
Dizziness	1 (0.2)
Hyperaesthesia	1 (0.2)
Migraine	1 (0.2)
Visual field defect	1 (0.2)
Application site rash	1 (0.2)
Chest discomfort	1 (0.2)
Feeling abnormal	1 (0.2)
Injection site pain	1 (0.2)
Arthralgia	1 (0.2)
Muscular weakness	1 (0.2)
Pain in extremity	1 (0.2)
Rash	1 (0.2)
Dry skin	1 (0.2)
Rash generalized	1 (0.2)
Dehydration	1 (0.2)
Dysuria	1 (0.2)
Vertigo	1 (0.2)
Hypersensitivity	1 (0.2)
Disorientation	1 (0.2)

- 30 (5.1%) patients experienced at least one treatment-emergent adverse event
- The most frequently reported adverse events (>0.5%) were headache, dysgeusia, and fatigue
- Hypersensitivity reaction was the single drug related Grade 3 adverse events reported in one patient with significant history of allergic reactions

Lantheus Holdings



Credit Suisse 29th Annual Healthcare Conference

November 11, 2020

FIND > FIGHT > FOLLOW